6
T. THI KIEU MY ET AL.
(C-4’’), 76.2 (C-5’’), 70.1 (C-6’’); Xyl-1 (term): dC 105.5 (C-1’’’), 74.7 (C-2’’’), 78.2 (C-3’’’),
71.1 (C-4’’’), and 66.7 (C-5’’’).
3.3.2. 3β,12β,20S-trihydroxydammar-24-ene-3-O-β-D-xylopyranosyl-20-O-
[β-D-xylopyranosyl-(1!6)-β-D-glucopyranoside] (2)
White, amorphous powder. HR-ESI-MS m/z 885.5215 [M‒ H]‒ (Calcd. for C46H77O16,
1
885.5211). H NMR (CD3OD, 500 MHz): dH 1.70 (1H, m, H-1a), 0.97 (1H, m, H-1b), 1.80
(1H, m, H-2a), 1.68 (1H, m, H-2b), 3.10 (1H, d, J ¼ 9.5 Hz, H-3), 0.76 (1H, d, J ¼ 11.0 Hz,
H-5), 1.54 (1H, m, H-6a), 1.46 (1H, m, H-6b), 1.54 (1H, m, H-7a), 1.28 (1H, m, H-7b), 1.41
(1H, m, H-9), 1.77 (1H, m, H-11a), 1.27 (1H, m, H-11b), 3.70 (1H, m, H-12), 1.71 (1H, m,
H-13), 1.55 (1H, m, H-15a), 1.02 (1H, m, H-15b), 1.79 (1H, m, H-16a), 1.33 (1H, m,
H-16b), 2.26 (1H, m, H-17), 0.98 (3H, s, H-18), 0.90 (3H, s, H-19), 1.34 (3H, s, H-21), 1.77
(1H, m, H-22a), 1.50 (1H, m, H-22b), 2.14 (1H, m, H-23a), 2.02 (1H, m, H-23b), 5.11 (1H,
t, J ¼ 7.0 Hz, H-24), 1.67 (3H, s, H-26), 1.61 (3H, s, H-27), 1.02 (3H, s, H-28), 0.83 (3H, s,
H-29), 0.90 (3H, s, H-30); C-3-Xyl-1 (inner): dH 4.24 (1H, d, J ¼ 7.5 Hz, H-1’), 3.16 (1H, m,
H-2’), 3.27 (1H, m, H-3’), 3.47 (1H, m, H-4’), 3.16 (2H, t, J ¼ 10.5 Hz, H-5’); C-20-Glc-1
(inner): dH 4.55 (1H, d, J ¼ 7.5 Hz, H-1’’), 3.11 (1H, m, H-2’’), 3.33 (1H, m, H-3’’), 3.31 (1H,
m, H-4’’), 3.38 (1H, m, H-5’’), 4.00 (1H, dd, J ¼ 2.5, 11.0 Hz, H-6’’a), 3.73 (1H, br d,
J ¼ 11.0 Hz, H-6’’b); Xyl-1 (term): dH 4.28 (1H, d, J ¼ 7.5 Hz, H-1’’’), 3.19 (1H, m, H-2’’’),
3.29 (1H, m, H-3’’’), 3.44 (1H, m, H-4’’’), 3.83 (1H, m, H-5’’’a), and 3.18 (1H, t, J ¼ 10.5 Hz,
H-5’’’b). 13C NMR (CD3OD, 125 MHz): dC 40.2 (C-1), 27.2 (C-2), 90.4 (C-3), 40.3 (C-4), 57.5
(C-5), 19.2 (C-6), 35.8 (C-7), 40.9 (C-8), 51.1 (C-9), 37.9 (C-10), 30.8 (C-11), 71.6 (C-12),
49.7 (C-13), 52.4 (C-14), 31.5 (C-15), 27.3 (C-16), 52.9 (C-17), 16.3 (C-18), 16.7 (C-19),
84.9 (C-20), 22.4 (C-21), 36.7 (C-22), 23.8 (C-23), 126.0 (C-24), 132.1 (C-25), 25.9 (C-26),
18.0 (C-27), 28.4 (C-28), 16.8 (C-29), 17.4 (C-30); C-3-Xyl-1 (inner): dC 107.3 (C-1’), 75.4
(C-2’), 77.9 (C-3’), 71.2 (C-4’), 66.7 (C-5’); C-20-Glc-1 (inner): dC 98.0 (C-1’’), 75.2 (C-2’’),
78.5 (C-3’’), 71.4 (C-4’’), 76.6 (C-5’’), 70.0 (C-6’’); Xyl-1 (term): dC 105.4 (C-1’’’), 74.7 (C-2’’’),
77.4 (C-3’’’), 71.1 (C-4’’’), and 66.6 (C-5’’’).
3.3.3. 12-oxo-3β,20S-dihydroxydammar-24-ene-3-O-[β-D-glucopyranosyl(1!2)-β-D-
glucopyrano syl]-20-O-[β-D-xylopyranosyl-(1!6)-β-D-glucopyranoside] (3)
White, amorphous powder. HR-ESI-MS m/z 1075.5663 [M ‒ H]‒ (Calcd. for C53H87O22,
1
1075.5668). H NMR (CD3OD, 500 MHz): dH 1.60 (1H, m, H-1a), 1.03 (1H, m, H-1b), 1.99
(1H, m, H-2a), 1.74 (1H, m, H-2b), 3.20 (1H, d, J ¼ 9.5 Hz, H-3), 0.82 (1H, d, J ¼ 11.0 Hz,
H-5), 1.66 (1H, m, H-6a), 1.57 (1H, m, H-6b), 1.55 (1H, m, H-7a), 1.42 (1H, m, H-7b), 1.73
(1H, m, H-9), 2.43 (1H, m, H-11a), 2.13 (1H, m, H-11b), 3.32 (1H, d, J ¼ 9.0 Hz, H-13),
1.82 (1H, m, H-15a), 1.16 (1H, m, H-15b), 1.92 (1H, m, H-16a), 1.75 (1H, m, H-16b), 2.52
(1H, m, H-17), 1.28 (3H, s, H-18), 1.01 (3H, s, H-19), 1.13 (3H, s, H-21), 1.66 (2H, m,
H-22), 2.03 (2H, m, H-23), 5.12 (1H, t, J ¼ 7.0 Hz, H-24), 1.70 (3H, s, H-26), 1.64 (3H, s,
H-27), 1.10 (3H, s, H-28), 0.90 (3H, s, H-29), 0.76 (3H, s, H-30); C-3-Glc-1 (inner): dH 4.44
(1H, d, J ¼ 7.5 Hz, H-1’), 3.60 (1H, m, H-2’), 3.33 (1H, m, H-3’), 3.30 (1H, m, H-4’), 3.43
(1H, m, H-5’), 3.84 (1H, br d, J ¼ 11.0 Hz, H-6’a), 3.64 (1H, dd, J ¼ 5.5, 11.0 Hz, H-6’b);
Glc-2 (term): dH 4.69 (1H, d, J ¼ 7.5 Hz, H-1’’), 3.24 (1H, dd, J ¼ 7.5, 9.0 Hz, H-2’’), 3.36
(1H, m, H-3’’), 3.26 (1H, m, H-4’’), 3.29 (1H, m, H-5’’), 3.86 (1H, dd, J ¼ 2.5, 11.0 Hz,